ESO-T01 delivers its first four multiple myeloma case reports.
ApexOnco Front Page
Recent articles
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
But with Brukinsa and degraders looming, will fixed dosing make the difference?
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.
